Private equity firm Carousel Capital has finalized a continuation fund for Ethos, a health tech company specializing in insurance claims and medical management solutions. The firm initially partnered with Ethos in 2020. This financial move signals confidence in Ethos's long-term growth prospects and the potential for increased returns on the initial investment.

Dextra Partners served as an anchor investor for the deal. The capital infusion will fuel Ethos's strategic initiatives. It will enable further investment in technology and expansion of its medical management offerings. Continuation funds are increasingly common, allowing firms to hold onto promising portfolio companies longer and provide more capital.

This type of fund structure allows Carousel Capital to continue supporting Ethos's growth trajectory. It also provides existing investors with an opportunity to remain invested. The health tech sector has seen substantial investment, driven by demand for innovative solutions. This deal reflects the ongoing interest in companies improving healthcare efficiency.

What's next for Ethos? The company is likely to focus on integrating its latest technology advancements and expanding its service offerings. Investors will be watching for further acquisitions or partnerships. These moves will solidify its market position and potential for future growth within the evolving health tech space.